Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log

This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record.

September 1, 2025

Assessed

• NCGC00135472 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• TC-O 9311 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

August 31, 2025

Assessed

• Draft:Claisen Inc (talk) assessed. Importance assessed as NA-Class. (rev · t)
• Morten Asser Karsdal (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Unknown-Class. (rev · t)

Removed

• Cicortonide (talk) removed.

August 30, 2025

Assessed

• JNJ-63533054 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

August 29, 2025

Assessed

• Draft:Katrina A Bramstedt (talk) assessed. Importance assessed as NA-Class. (rev · t)

August 28, 2025

Reassessed

• Onasemnogene abeparvovec (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
• Procaine benzylpenicillin (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)

Assessed

• Compound 9 (opioid antagonist) (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Draft:Jacob Lalezari (talk) assessed. Importance assessed as NA-Class. (rev · t)

August 27, 2025

Assessed

• Amy Lasek (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Draft:Pill Clarity (talk) assessed. Importance assessed as NA-Class. (rev · t)

August 26, 2025

Reassessed

• Allen & Hanburys (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)
• CeraVe (talk) reassessed. Importance rating changed from Unknown-Class to Low-Class. (rev · t)
• Cinchocaine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Cipralisant (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t) Importance rating changed from Unknown-Class to Low-Class. (rev · t)
• Cost-effectiveness analysis (talk) reassessed. Quality rating changed from Redirect-Class to Start-Class. (rev · t) Importance rating changed from NA-Class to Unknown-Class. (rev · t)
• Medetomidine/vatinoxan (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Mepenzolate (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Metapramine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Mexazolam (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Midol (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Minaprine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
• Omberacetam (talk) reassessed. Quality rating changed from Redirect-Class to Start-Class. (rev · t)
• Pamabrom (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed

• Category:Drug classes defined by psychological effects (talk) assessed. Quality assessed as Category-Class. (rev · t) Importance assessed as NA-Class. (rev · t)
• R-5260 (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
• Zopapogene imadenovec (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Mid-Class. (rev · t)

Removed

• Draft:No Observed Adverse Effect Level Therapy (talk) removed.